Edgewise Therapeutics (EWTX) announced changes to its executive team. These changes include the addition of Robert Blaustein, joining the company as chief development officer and the promotion of Behrad Derakhshan from chief business officer to COO. Blaustein joins the company as chief development officer, responsible for leading EDG-7500, a cardiac sarcomere modulator in Phase 2 development, as well as the cardiovascular and cardiometabolic pipeline. Blaustein joins from Merck (MRK) where he was most recently associate VP and the Atherosclerosis Section Head in the Atherosclerosis and Metabolism Clinical Research Department. Semigran, current CDO, will depart from the company and will serve as a clinical advisor for a period to ensure a smooth transition. These changes to the Edgewise executive team are effective immediately.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics initiated with a Hold at Stifel
- Edgewise Therapeutics price target raised to $50 from $45 at Evercore ISI
- Edgewise Therapeutics Reports Promising Phase 2 Trial Results
- Edgewise Therapeutics price target raised to $50 from $44 at Leerink
- Morning Movers: Viridian and Edgewise jump following successful trials